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***Dear Editor,***

After the *JAK2* V617F mutation, insertion and/or deletion (indel) mutations of *CALR* exon 9 are the second most common driver mutations in the myeloproliferative neoplasms (MPN) of essential thrombocythemia and primary myelofibrosis and their detection is considered a major diagnostic criterion for these malignancies. It is becoming increasingly apparent that MPNs harboring *CALR* mutations (along with the mutations of *JAK2* V617F and *MPL* exon 10) may occur in patients with *BCR-ABL1*-positive chronic myeloid leukemia (CML) as evidenced by a wave of recently reported cases. The *CALR*-positive MPN and CML may appear concurrently with composite morphology or sequentially with either malignancy revealed as a consequence of specific treatment for one of the malignancies (Table 1[(Tab. 1)](#T1){ref-type="fig"}; References in Table 1: Balducci et al., 2019\[[@R1]\]; Blouet et al., 2018\[[@R2]\]; Boddu et al., 2018\[[@R3]\]; Bonzheim et al., 2015\[[@R4]\]; Cabagnols et al., 2015\[[@R5]\]; da Costa et al., 2019\[[@R6]\]; De Roeck et al., 2018\[[@R7]\]; Diamond et al., 2016\[[@R8]\]; Dogliotti et al., 2017\[[@R9]\]; Gilles et al., 2015\[[@R10]\]; Guidotti et al., 2020\[[@R11]\]; Jeromin et al., 2017\[[@R12]\]; Kandarpa et al., 2017\[[@R13]\]; Klairmont et al., 2018\[[@R14]\]; Lewandowski et al, 2018\[[@R15]\]; Loghavi et al., 2015\[[@R16]\]; Nomani et al., 2016\[[@R18]\]; Pagoni et al., 2014\[[@R19]\]; Seghatoleslami et al, 2016\[[@R20]\]; Xia et al., 2019\[[@R21]\]). Review of patients shows that the presenting malignancy was unknown in one case, CML in 11/24 (46 %) and *CALR*-mutated MPN in the remaining 12/24 (50 %) cases. Evidence exists for molecular abnormalities occurring within a single clone and in distinct clonal populations.

While co-existence of CML and another MPN has clinical relevance with respect to selection and timing of tyrosine kinase inhibitor therapy, there is currently insufficient follow-up data to ascertain overall survival of such cases. There is limited value in assessing the *JAK2*V617F mutation in all newly presenting CML cases (McCarron et al., 2012\[[@R17]\]): screening for the less frequent *CALR* and *MPL* mutations in all likelihood would show a similar redundancy. Given the low incidence but increasing awareness of co-existing CML and MPN, testing for the relevant rearrangement should therefore be implemented when there is clinical, hematological or morphological evidence.
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